E
Evaxion Biotech AS (EVAX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$2.77
+0.03 (+1.09%)
Market Cap: $25.27M
Last updated: Nov 17, 2026 at 11:01 AM ET
Evaxion Biotech AS (EVAX) Valuation Multiples
Evaxion Biotech AS (EVAX) trades at 0.2x sales and 0.1x book value. Its P/B of 0.1x is below its 5-year median of 3.3x. Its forward P/E is 3.6x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 3.6x |
| Price to sales | 0.2x |
| Price to book | 0.1x |
| EV/FCF | 0.4x |
| PEG | N/A |
| FCF yield | -1521.4% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/B | 0.1x | 3.3x | N/A |
Valuation History
Over the 3 of the 5 year ends shown that have a P/S, its P/S ranged from 0.7x in 2025 to 321.0x in 2023.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $4.77 | 0.7x | 1.8x |
| 2024 | $4.23 | 1.8x | N/A |
| 2023 | $34.29 | 321.0x | N/A |
| 2022 | $88.75 | N/A | 3.9x |
| 2021 | $221.00 | N/A | 3.7x |
Frequently Asked Questions About EVAX
What is EVAX's forward P/E ratio?
Evaxion Biotech AS has a forward P/E ratio of 3.6x.
What is EVAX's price to sales ratio?
Evaxion Biotech AS has a price to sales ratio of 0.2x.
EVAX pages: Overview, Earnings, Forecast, Valuation, Competitors